Jump to main content
Jump to site search

Issue 1, 2015
Previous Article Next Article

Cationic azacryptands as selective three-way DNA junction binding agents

Author affiliations

Abstract

DNA damaging agents are among the most powerful anticancer drugs currently in clinical use. As an alternative to irreversible nucleobase damage and DNA strand breaks, the non-covalent stabilization of unusual, non-B DNA structures is currently emerging as a promising way to cause DNA damage with a high level of specificity. One of such non-B DNA structures is the three-way DNA junction: this Y-shaped multi-stranded architecture may act as an impediment to many DNA transactions, being therefore regarded as an invaluable target to create genomic defects that are improperly dealt with by cancer cells only. Herein, we report on a series of cationic azacryptands that make excellent candidates for assessing and harnessing the actual therapeutic potential of three-way DNA junction interacting compounds.

Graphical abstract: Cationic azacryptands as selective three-way DNA junction binding agents

Back to tab navigation

Supplementary files

Article information


Submitted
29 Aug 2014
Accepted
15 Oct 2014
First published
15 Oct 2014

Org. Biomol. Chem., 2015,13, 215-222
Article type
Paper
Author version available

Cationic azacryptands as selective three-way DNA junction binding agents

J. Novotna, A. Laguerre, A. Granzhan, M. Pirrotta, M. Teulade-Fichou and D. Monchaud, Org. Biomol. Chem., 2015, 13, 215
DOI: 10.1039/C4OB01846J

Social activity

Search articles by author

Spotlight

Advertisements